SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signali...
SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
SGLT2 inhibitors, a T2DM medication to lower blood glucose, markedly improve cardiovascular outcomes but the underlying mechanism(s) are not fully understood. SGLT2i's produce a unique metabolic pattern by lowering blood glucose without increasing insulin while increasing ketone body and glucagon levels and reducing body weight. We tested if glucag...
Alternative Titles
Full title
SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_e4b485641d78496b9714711ae24f8c10
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e4b485641d78496b9714711ae24f8c10
Other Identifiers
ISSN
1475-2840
E-ISSN
1475-2840
DOI
10.1186/s12933-024-02491-w
